Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | PPID | Q08752 | 1/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28016251 | 1.00 | DRD1 (0.50) | DRD1PPIDMETAP2METAP1L3MBTL1 | |
| SCHEMBL112747 | 0.94 | PPID (0.53) | DRD1PPIDMETAP2METAP1L3MBTL1 | |
| SCHEMBL112746 | 0.94 | PPID (0.53) | DRD1PPIDMETAP2METAP1L3MBTL1 | |
| SCHEMBL3925234 | 0.85 | DRD1 (0.45) | DRD1PPIDMETAP2METAP1 | |
| SCHEMBL15047985 | 0.85 | DRD1 (0.45) | DRD1PPIDMETAP2METAP1 | |
| SCHEMBL3925240 | 0.85 | DRD1 (0.45) | DRD1PPIDMETAP2METAP1 | |
| SCHEMBL14519884 | 0.84 | METAP2 (0.52) | PPIDMETAP2METAP1L3MBTL1USP2 | |
| SCHEMBL8206011 | 0.84 | DRD1 (0.46) | DRD1PPIDMETAP2METAP1FNTA | |
| SCHEMBL113048 | 0.81 | L3MBTL1 (0.44) | DRD1PPIDL3MBTL1USP2GAA | |
| SCHEMBL113049 | 0.81 | L3MBTL1 (0.44) | DRD1PPIDL3MBTL1USP2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623338-B2 | Methionine-derived peptidomimetics and their use in the protection of mitochondria of cutaneous cells | EXSYMOL S.A.M. (MC) | 2014-01-07 | — | — | US | disclosed |
| EP-2431356-B1 | Peptidomimetic methionine derivatives as well as their use in the protection of skin cells | EXSYMOL SA (MC) | 2013-11-13 | — | — | EP | disclosed |
| US-20120070394-A1 | METHIONINE-DERIVED PEPTIDOMIMETICS AND THEIR USE IN THE PROTECTION OF MITOCHONDRIA OF CUTANEOUS CELLS | EXSYMOL S.A.M. (MC) | 2012-03-22 | — | — | US | disclosed |
| EP-2431356-A1 | Peptidomimetic methionine derivatives as well as their use in the protection of skin cells | Exsymol S.A.M. (MC) | 2012-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070394-A1 | METHIONINE-DERIVED PEPTIDOMIMETICS AND THEIR USE IN THE PROTECTION OF MITOCHONDRIA OF CUTANEOUS CELLS | MTR, ARG2, MARS2 | DRD1 2015/4885PPID 495/4885METAP2 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.